en · de · es · pt
compound-index.peptides6908.com › Faq › Background And Molecular Profile — Explained

Background And Molecular Profile — Explained

By Editorial Desk · published 2025-09-30 · last reviewed 2025-11-08 · Faq

The short version of thymosin alpha 1 fits in a sentence. The long version — which is the one that helps — is below.

Reviewed 2025-11-08. Anything still debated is marked as such rather than presented as settled.

Background and Molecular Profile

The peptide is generated in cells by cleavage of prothymosin alpha, a larger acidic protein encoded by the PTMA gene. Prothymosin alpha is expressed in many tissues, not only in the thymus, and its functions include nuclear roles in chromatin-related processes. The 28-residue fragment corresponds to the N-terminal portion of that precursor. How the cleavage occurs and how the fragment's concentration is regulated remain open questions; circulating amounts are small and difficult to measure reliably with routine assays.

Thymosin alpha 1 is a short peptide first isolated from bovine thymus tissue in the early 1970s during fractionation work aimed at identifying factors that influence T cell development. It belongs to a family of acidic thymic peptides, and the original preparations contained several components that were later separated by chromatography. The compound is now produced synthetically rather than extracted from tissue, which removes batch variability tied to animal sourcing. Researchers describe it as an immunomodulatory peptide because laboratory studies show effects on several cell types of the innate and adaptive immune systems.

The molecule consists of 28 amino acid residues with an acetyl group attached to the N-terminal serine. Its sequence is acidic overall, with several glutamic and aspartic acid residues distributed along the chain and no cysteine, so disulfide bridges do not form. The peptide carries a net negative charge at physiological pH. Because the N-terminus is blocked, the intact molecule resists degradation by many aminopeptidases, which contributes to its stability in biological fluids.

Background and Molecular Identity

The peptide was identified during work in the 1970s on thymosin fraction 5, a partially purified extract of calf thymus. Investigators separated that mixture and characterized individual components, one of which they named thymosin alpha-1. The same compound later received the international nonproprietary name thymalfasin. Commercial material is produced by solid-phase peptide synthesis rather than by extraction, so synthetic and natural forms share an identical sequence. Naming conventions vary across the literature, and readers should distinguish the alpha-1 peptide from other thymosins that have unrelated sequences and functions.

Thymosin beta-4 is a separate 43-residue peptide that binds actin and participates in cell migration; it shares no sequence similarity with thymosin alpha-1 despite the common family name. Other preparative materials, such as thymosin fraction 5 and thymopoietin, contain distinct mixtures or peptides. The shared thymosin label reflects the tissue of origin used in early purification, not a common structural core. Treating these molecules as interchangeable is a frequent source of confusion in laboratory reports and in popular summaries alike.

Thymosin-alpha-1 at a glance

PropertyValueNotes
Chemical classAcetylated peptideN-terminal acetyl group blocks aminopeptidase attack
Residue count28 amino acidsMatches the N-terminus of prothymosin alpha
Molecular massAbout 3,108 DaValue for the free, unmodified peptide
Isoelectric pointApproximately 4.2Acidic; net negative charge at neutral pH
Encoding genePTMAHuman gene for the precursor protein

Molecular Identity Of Thymosin Alpha-1

Most published studies on thymosin alpha-1 report changes in immune measurements rather than clinical outcomes, and findings differ across designs and populations. Whether the peptide signals through one defined receptor or through several less specific interactions remains an open question. Its reported circulation half-life of a few hours complicates comparison of dosing schedules across trials. Mechanistic claims are frequently drawn from isolated cell cultures, and how far those results extend to whole organisms is unresolved.

Thymosin alpha-1 is a synthetic peptide of 28 amino acids whose sequence matches the amino-terminal region of prothymosin alpha. The chain is acetylated at its first residue and contains one disulfide bridge between two cysteine residues, which folds the molecule into a compact loop. Its molecular formula, C129H215N33O55, corresponds to a monoisotopic mass of roughly 3,106 daltons. Material used in laboratories is made by solid-phase synthesis rather than isolated from animal tissue.

Related pages on this site

Molecular Structure and Biological Background

The peptide was described in the 1970s as a component of thymic extracts, and early research focused on restoring immune function in immunodeficiency states. A synthetic version entered clinical development in the 1980s and is approved as a drug in several countries for conditions such as chronic hepatitis B and certain immunodeficiencies. Approval status varies widely by jurisdiction, and in the United States it is not an approved therapeutic. Regulatory and clinical positions differ, so statements about efficacy should be tied to specific indications and studies.

Thymosin alpha-1 is a synthetic peptide of 28 amino acids, corresponding to the N-terminal fragment of prothymosin alpha. Its sequence begins with acetylation at the N-terminus, a modification that affects stability and receptor interaction. The peptide is acidic, with a calculated isoelectric point near 4.2, and carries no disulfide bonds, so its secondary structure is largely flexible in solution. Molecular mass is approximately 3108 daltons. The native form was first isolated from bovine thymus tissue, while pharmaceutical material is produced by solid-phase peptide synthesis.

Background from the literature

=== 9 April === Ukraine started electricity exports for the first time since six months after the invasion. Energy exports had been stopped due to multiple strikes on the electrical infrastructure. Ukrainian Energy Minister Herman Halushchenko stated that the electrical system had been producing extra capacity for almost two months.

=== Cancer treatment side effects === LLLT has been studied as a way to reduce pain and swelling in breast-cancer related lymphedema. The 2015 systematic review and meta-analysis by Smoot, Chiavola-Larson, et al found "Moderate-strength evidence supports LLLT in the management of [breast cancer related lymphoedema], with […] reductions in volume and pain immediately after conclusion of LLLT treatments. Greater reductions in volume [of lymph nodes or surrounding tissues] were found with the use of LLLT than in treatments without it."

A polymer () is a substance or material that consists of very large molecules, or macromolecules, that are constituted by many repeating subunits derived from one or more species of monomers. Due to their broad spectrum of properties, both synthetic and natural polymers have essential and ubiquitous roles in everyday life. Polymers range from familiar synthetic plastics such as polystyrene to natural biopolymers such as DNA and proteins that are fundamental to biological structure and function. Polymers, both natural and synthetic, are created via polymerization of many small molecules, known as monomers. Their consequently large molecular mass, relative to small molecule compounds, produces unique physical properties including toughness, high elasticity, viscoelasticity, and a tendency to form amorphous and semicrystalline structures rather than crystals. Polymers are studied in the fields of polymer science (which includes polymer chemistry and polymer physics), biophysics and materials science and engineering. Historically, products arising from the linkage of repeating units by covalent chemical bonds have been the primary focus of polymer science. An emerging important area now focuses on supramolecular polymers formed by non-covalent links. Polyisoprene of latex rubber is an example of a natural polymer, and the polystyrene of styrofoam is an example of a synthetic polymer.

The Belize currency is pegged to the US dollar and banks in Belize offer non-residents the ability to establish accounts, so drug traffickers and money launderers are attracted to banks in Belize. As a result, the United States Department of State has, since 2014, named Belize as one of the world's "major money laundering countries".

Sources: en.wikipedia.org

Further detail

== B == Baeyer–Drewsen indigo synthesis (also commonly incorrectly named Baeyer–Drewson indigo synthesis) Baeyer–Villiger oxidation, Baeyer–Villiger rearrangement Bakeland process (Bakelite) Baker–Venkataraman rearrangement, Baker–Venkataraman transformation Baldwin's rules Bally–Scholl synthesis Balz–Schiemann reaction Bamberger rearrangement Bamberger triazine synthesis Bamford–Stevens reaction Barbier reaction Barbier–Wieland degradation Bardhan–Sengupta phenanthrene synthesis Barfoed's test Bargellini reaction Bartoli indole synthesis, Bartoli reaction Barton decarboxylation Barton reaction Barton–Kellogg reaction Barton–McCombie reaction, Barton deoxygenation Barton-Zard Synthesis Barton vinyl iodine procedure Baudisch reaction Bayer test Baylis–Hillman reaction Bechamp reaction Bechamp reduction Beckmann fragmentation Beckmann rearrangement Bellus–Claisen rearrangement Belousov–Zhabotinsky reaction Benary reaction Benedict's reagent Benkeser reaction Benzidine rearrangement Benzilic acid rearrangement Benzoin condensation Bergman cyclization Bergmann azlactone peptide synthesis Bergmann degradation Bergmann–Zervas carbobenzoxy method Bernthsen acridine synthesis Bestmann's reagent Betti reaction Biginelli pyrimidine synthesis Biginelli reaction Bingel reaction Birch reduction Bischler–Möhlau indole synthesis Bischler–Napieralski reaction Biuret test Blaise ketone synthesis Blaise reaction Blanc reaction Blanc chloromethylation Blum–Ittah aziridine synthesis Bodroux reaction Bodroux–Chichibabin aldehyde synthesis Bogert–Cook synthesis Bohlmann-Rahtz pyridine synthesis Bohn–Schmidt reaction Boord olefin synthesis Borodin reaction Borsche–Drechsel cyclization Bosch–Meiser urea process Bosch reaction Bouveault aldehyde synthesis Bouveault–Blanc reduction Boyland–Sims oxidation Boyer Reaction Bredt's rule Brook rearrangement Brown hydroboration Bucherer carbazole synthesis Bucherer reaction Bucherer–Bergs reaction Buchner ring enlargement Büchner–Curtius–Schlotterbeck reaction Buchwald–Hartwig amination Bunnett reaction Burgess reagent

=== Recreational use === Recreational users report that a barbiturate high gives them feelings of relaxed contentment and euphoria. Physical and psychological dependence may also develop with repeated use. Chronic misuse of barbiturates is associated with significant morbidity. One study found that 11% of males and 23% of females with a sedative-hypnotic misuse die by suicide. Other effects of barbiturate intoxication include drowsiness, lateral and vertical nystagmus, slurred speech and ataxia, decreased anxiety, and loss of inhibitions. Barbiturates are also used to alleviate the adverse or withdrawal effects of illicit drug use, in a manner similar to long-acting benzodiazepines such as diazepam and clonazepam. Often polysubstance use occurs and barbiturates are consumed with or substituted by other available substances, most commonly alcohol. People who use substances tend to prefer short-acting and intermediate-acting barbiturates. The most commonly used are amobarbital (Amytal), pentobarbital (Nembutal), and secobarbital (Seconal). A combination of amobarbital and secobarbital (called Tuinal) is also highly used. Short-acting and intermediate-acting barbiturates are usually prescribed as sedatives and sleeping pills. These pills begin acting fifteen to forty minutes after they are swallowed, and their effects last from five to six hours. Slang terms for barbiturates include barbs, barbies, bluebirds, dolls, wallbangers, yellows, downers, goofballs, sleepers, 'reds & blues', and tooties.

Overall, 24 out of 25 patients treated with brentuximab vedotin and AVD achieved complete remission. Brentuximab vedotin is also being investigated as a substitute for vincristine (another mitotic inhibitor which prevents tubulin polymerization) in patients with being treated with CHOP (a combination of cyclophosphamide, hydroxydaunorubicin, vincristine, prednisone or prednisolone) for a non-Hodgkin lymphoma. A phase III clinical trial comparing the two combination therapies (CHOP and CHP-brentuximab vedotin) was completed in October 2020, with results published in 2021. The ECHELON-1 phase 3 trial compared brentuximab vedotin with bleomycin both in combination with adriamycin, vinblastine, dacarbazine (AVD) chemotherapy as a firstline treatment for advanced classical Hodgkin lymphoma. The outcome of the trial resulted in a positive recommendation by the Committee for Medicinal Products for Human Use (CHMP) as part of a combination treatment in adults with previously untreated CD30+ stage 3 Hodgkin lymphoma.

The European Centre for Disease Prevention and Control calculated that in 2015, there were 671,689 infections in the EU and European Economic Area caused by antibiotic-resistant bacteria, resulting in 33,110 deaths. Most were acquired in healthcare settings. In 2019 there were 133,000 deaths caused by AMR.

== Etymology == The genus Naegleria was established by Alexis Alexeieff in 1912, who grouped the flagellate amoeba. He coined the term Naegleria after Kurt Nägler, who researched amoebae. The species was named after Malcolm Fowler, an Australian pathologist at Adelaide Children's Hospital, who was the first author of the original series of case reports (British Medical Journal, starting 1965) of PAM.

Sources: en.wikipedia.org

Supporting material

=== Pharmacodynamics === Tiagabine acts a selective GABA transporter 1 (GAT-1) blocker and hence as a GABA reuptake inhibitor (GRI). The GAT-1 is one of at least four distinct GABA transporters (GATs), with the GAT-1 being the predominant subtype in the brain, accounting for 85% of GATs in this part of the body, and thought to be responsible for most γ-aminobutyric acid (GABA) reuptake in synapses. The drug has more than 1,000-fold selectivity for the GAT-1 over the GABA transporter 2 (GAT-2), GABA transporter 3 (GAT-3), and betaine/GABA transporter (BGT-1; GAT-4). It also shows no significant affinity for GABA receptors or numerous other targets. In addition, it does not affect key cardiac ion channels. Through GAT-1 blockade, tiagabine increases levels of GABA, the major inhibitory neurotransmitter in the central nervous system, and consequently increases GABA receptor activation and GABAergic signaling, including of both GABAA and GABAB receptors. The drug has been found to increase GABAergic signaling in the hippocampus, globus pallidus, ventral pallidum, and substantia nigra in animals. It produces anticonvulsant, neuroprotective, hypnotic, analgesic, and anxiolytic-like effects in animals. In rodent drug discrimination tests, tiagabine partially substituted for muscimol and diazepam but did not substitute for gaboxadol, phenobarbitol, or zolpidem. When tiagabine was used as the training drug however, gaboxadol near-fully substituted for tiagabine. Similarly, indiplon partially substituted for tiagabine.

A large number of benzodiazepine derivatives have been synthesised and their structure-activity relationships explored in detail. This chart contains binding data for benzodiazepines and related drugs investigated by Roche up to the late 1990s (though in some cases the compounds were originally synthesised by other companies such as Takeda or Upjohn). Other benzodiazepines are also listed for comparison purposes, but it does not however include binding data for;

Hemoglobin (haemoglobin, Hb or Hgb) is a protein containing iron that facilitates the transportation of oxygen in red blood cells. Almost all vertebrates contain hemoglobin, with the sole exception of the fish family Channichthyidae. Hemoglobin in the blood carries oxygen from the respiratory organs (lungs or gills) to the other tissues of the body, where it releases the oxygen to enable aerobic respiration which powers an animal's metabolism. A healthy human has 12 to 20 grams of hemoglobin in every 100 mL of blood. Hemoglobin is a metalloprotein, a chromoprotein, and a globulin. In mammals, hemoglobin makes up about 96% of a red blood cell's dry weight (excluding water), and around 35% of the total weight (including water). Hemoglobin has an oxygen-binding capacity of 1.34 mL of O2 per gram, which increases the total blood oxygen capacity seventy-fold compared to dissolved oxygen in blood plasma alone. The mammalian hemoglobin molecule can bind and transport up to four oxygen molecules. Hemoglobin also transports other gases. It carries off some of the body's respiratory carbon dioxide (about 20–25% of the total) as carbaminohemoglobin, in which CO2 binds to the heme protein. The molecule also carries the important regulatory molecule nitric oxide bound to a thiol group in the globin protein, releasing it at the same time as oxygen.

Biomass is a form of renewable energy useful as fuel and as a source of some chemical products. Relative to coal and petroleum however, the energy content of biomass is low. Compared to traditional fossil fuels, biomass has a high oxygen content. Its carbon is partially combusted, so to speak. One such notable example is the production of bio-ethanol. There is a general classification of biomass that is produced or sourced for conversion processes. Biofuels such as bioethanol and biodiesel, and bioplastics, are typically derived from primary or “first-generation” source energy-dense plants and oils such as rapeseed, sugarcane, or corn. Their high content of sugars and oils makes them ideal as feedstocks, however, there are drawbacks to their use. As well as inflating the price of the chosen crop due to increased demand, arable land that would otherwise be used to grow food for human and animal consumption is rendered unavailable. Secondary or “second-generation” source biomass encompasses a much wider variety of plant and animal matter. It may be derived from a relatively pure source, such as wood chippings or grass, or it may be a less well defined solid waste stream. This type of biomass is far more challenging to work with, as it contains a more varied mixture of compounds that cannot be easily converted into useful products.

Ready to drink chocolate milk is produced by homogenization. At or below room temperature, chocolate is a solid, which does not dissolve, but instead remains a powdered solid suspended in milk. The suspension must be stabilized, otherwise, the powder will settle. Separation can be slowed by any of the following:

Sources: en.wikipedia.org

Frequently asked questions

How does thymosin alpha 1 differ from thymosin fraction 5?

Thymosin fraction 5 is a mixture of many peptides obtained from thymus tissue, while thymosin alpha 1 is a single defined 28-residue molecule. The two names appear together in older literature because the purified peptide was first obtained from that mixture.

Which gene encodes the precursor protein?

The precursor, prothymosin alpha, is encoded by the PTMA gene in humans. The 28-residue peptide corresponds to the N-terminal segment released from that larger protein.

Is the peptide found naturally in the human body?

It is produced as a fragment of prothymosin alpha and is present in many tissues. Circulating concentrations are low, which makes routine measurement difficult.

What is thymosin alpha-1?

It is a 28-residue synthetic peptide studied as an immune-modulating agent and approved as a drug in some countries. The sequence matches a naturally occurring fragment isolated from thymus tissue. It is not a hormone in the endocrine sense.

Network